Few public biotech companies disclose ESG steps; FDA effort to improve clinical trial diversity failed to make a difference for Black patients

"Everybody knows they need to think about it, but there is no consensus on what to do," said Julia Forbess, whose firm reviewed disclosures.  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by        STAT+: Few public biotech companies disclose environmental, social, and governance steps By Ed Silverman Adobe “Everybody knows they need to think about it, but there is no consensus on what to do,” said Julia Forbess, whose firm reviewed disclosures. Read More STAT+: FDA effort to improve clinical trial diversity failed to make a difference for Black patients, study finds By Ed Silverman SAUL LOEB/AFP via Getty Images “It’s a very complicated process to improve trial enrollment,” said study co-author Angela Green. “But we need to induce change.” Read More STAT+: Key Democrat moves to crack down on FDA accelerated approvals By Nicholas Florko Zach Gibson/Getty Images Rep. Frank Pallone’s new bill would dramatically crack down on the Food and Drug Administration's so-called accelerated approval program. Read More Sponsor content by SUFFOLK UNIVERSITY BOSTON Rapidly evolving technology demands leadership that keeps pace Driven by scientific discovery, competition, and ever-increasing demand, the life sciences industry produces pioneering therapies and meets novel challenges. Success in the life sciences requires a firm grasp of intellectual property protection, regulatory compliance, and continually advancing fundamental science, as well as their complex intersections. Discover how a Master of Science in Law: Life Sciences bridges boundaries separating science, law, and business and prepares leaders for success in the dynamic biotech and pharma sectors. STAT+: With cash running short, Bluebird Bio and its gene therapies face uncertain future By Adam Feuerstein Ruby Wallau for STAT The troubled developer of gene therapies warned there is “substantial doubt” about its ability to remain in business after this year. Read More Monday, March 7, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser